New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
05:11 EDTPRXL, SGYPSynergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C
Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
News For SGYP;PRXL From The Last 14 Days
Check below for free stories on SGYP;PRXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
12:00 EDTSGYPSynergy Pharmaceuticals rises 14.1%
Subscribe for More Information
April 23, 2014
06:53 EDTPRXLFood & Drug Law Institute to hold a conference
Subscribe for More Information
April 17, 2014
09:10 EDTSGYPSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Synergy Pharmaceuticals' (SGYP) Plecanatide for Irritable Bowel Disease with constipation on an Analyst/Industry conference call to be held on April 17 at 11 am.
April 14, 2014
06:06 EDTPRXLPAREXEL appoint Peter Steiger as Chief Scientific Officer for Medical Imaging
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use